← Back to Screener
Agios Pharmaceuticals, Inc. (AGIO)
Price$27.07
Favorite Metrics
Price vs S&P 500 (26W)-22.22%
Price vs S&P 500 (4W)16.64%
Market Capitalization$1.54B
P/E Ratio (Annual)2.61x
All Metrics
Book Value / Share (Quarterly)$20.41
P/TBV (Annual)1.13x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)55.97%
Cash Flow / Share (Quarterly)$-6.46
Price vs S&P 500 (YTD)24.96%
Gross Margin (TTM)88.26%
Net Profit Margin (TTM)-764.01%
EPS (TTM)$-7.12
10-Day Avg Trading Volume0.88M
EPS Excl Extra (TTM)$-7.12
Revenue Growth (5Y)4.67%
EPS (Annual)$-7.12
ROI (Annual)-34.60%
Gross Margin (Annual)88.26%
Net Profit Margin (5Y Avg)-445.03%
Cash / Share (Quarterly)$14.62
Revenue Growth QoQ (YoY)86.09%
P/E Normalized (Annual)2.61x
ROA (Last FY)-31.82%
Revenue Growth TTM (YoY)48.03%
EBITD / Share (TTM)$-8.02
ROE (5Y Avg)13.77%
Operating Margin (TTM)-873.87%
Cash Flow / Share (Annual)$-6.46
P/B Ratio1.29x
P/B Ratio (Quarterly)1.33x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)26.81x
ROA (TTM)-28.92%
EV / EBITDA (TTM)2.27x
EPS Incl Extra (Annual)$-7.12
Current Ratio (Annual)11.46x
Quick Ratio (Quarterly)10.52x
3-Month Avg Trading Volume1.08M
52-Week Price Return29.48%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$15.87
P/S Ratio (Annual)28.46x
Asset Turnover (Annual)0.04x
52-Week High$46.00
Operating Margin (5Y Avg)-532.96%
EPS Excl Extra (Annual)$-7.12
CapEx CAGR (5Y)-21.96%
Tangible BV CAGR (5Y)24.00%
26-Week Price Return-13.47%
Quick Ratio (Annual)10.52x
13-Week Price Return22.31%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)11.46x
Enterprise Value$1,448.329
Revenue / Share Growth (5Y)0.19%
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)28.77%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.21x
Pretax Margin (Annual)-765.89%
Cash / Share (Annual)$14.62
3-Month Return Std Dev43.05%
Gross Margin (5Y Avg)90.54%
Net Income / Employee (TTM)$-1
ROE (Last FY)-34.60%
EPS Basic Excl Extra (Annual)$-7.12
Receivables Turnover (TTM)7.36x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-7.12
Receivables Turnover (Annual)7.36x
ROI (TTM)-31.07%
P/S Ratio (TTM)28.46x
Pretax Margin (5Y Avg)-421.16%
Revenue / Share (Annual)$0.93
Tangible BV / Share (Annual)$20.00
Price vs S&P 500 (52W)-5.62%
Year-to-Date Return29.10%
5-Day Price Return6.00%
EPS Normalized (Annual)$-7.12
ROA (5Y Avg)12.81%
Net Profit Margin (Annual)-764.01%
Month-to-Date Return3.87%
Cash Flow / Share (TTM)$-3.84
EBITD / Share (Annual)$-8.02
EPS Growth (3Y)-24.03%
Operating Margin (Annual)-873.87%
ROI (5Y Avg)13.76%
EPS Basic Excl Extra (TTM)$-7.12
P/TBV (Quarterly)1.41x
P/B Ratio (Annual)1.33x
Inventory Turnover (TTM)0.21x
Pretax Margin (TTM)-765.89%
Book Value / Share (Annual)$20.41
Price vs S&P 500 (13W)19.45%
Beta0.77x
P/FCF (Annual)53.68x
Revenue / Share (TTM)$0.93
ROE (TTM)-31.07%
52-Week Low$22.24
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.06
4.06
4.06
4.06
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AGIOAgios Pharmaceuticals, Inc. | 28.46x | 48.03% | 88.26% | — | $27.07 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Agios Pharmaceuticals develops small-molecule medicines for rare hematologic diseases through cellular metabolism pathways. Its lead product, Pyrukynd (mitapivat), is a pyruvate kinase activator for hemolytic anemias, with additional pipeline candidates targeting sickle cell disease and myelodysplastic syndrome-associated anemia. The company addresses significant unmet medical needs in rare blood disorders.